See What HealthDay Can Do For You
Contact Us

Combination May Improve Prostate Cancer Prediction

Combined imaging, spectroscopy, and prostate-specific antigen highly accurate

MONDAY, Oct. 5 (HealthDay News) -- Combining endorectal MRI, magnetic resonance spectroscopy, and a low free-to-total prostate-specific antigen (PSA) ratio is highly accurate in predicting prostate cancer in men with high PSA levels, according to a European study in the October issue of Radiology.

Joan C. Vilanova, M.D., of Clinica Girona in Spain, and colleagues retrospectively analyzed whether the combination of free-to-total PSA ratio with endorectal MRI and magnetic resonance spectroscopy would increase the accuracy of prostate cancer detection in 54 men with PSA levels greater than 3 ng/mL, but less than 15 ng/mL, and a free-to-total PSA ratio of less than 20 percent.

The researchers found that the accuracy of prostate cancer detection (as determined by the area under the receiver operating characteristic curve) was 97.5 percent in a model incorporating MRI, magnetic resonance spectroscopy, and free-to-total PSA ratio. In contrast, the accuracy was 85.1 percent for models using only MRI, 87.2 percent for magnetic resonance spectroscopy alone, and 90.8 percent for MRI plus free-to-total PSA ratio.

"In conclusion, combining data from MRI, magnetic resonance spectroscopy, and free-to-total PSA ratio could improve prostate cancer detection in patients suspected of having prostate cancer and could obviate a substantial number of unnecessary biopsies," Vilanova and colleagues conclude.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.